Get started
Author

Clayton W. White

Observed name: Clayton White
ORCID: 0000-0002-4706-6424
Observed ORCID: 0000-0002-4706-6424
OpenAlex ID: A5044573254
A Probody T Cell–Engaging Bispecific Antibody Targeting EGFR and CD3 Inhibits Colon Cancer Growth with Limited Toxicity
2022 · Leila M. Boustany, Sherry L. LaPorte, et al. · Cancer Research · 70
Abstract A164: EGFR-CD3 bispecific Probody™ therapeutic induces tumor regressions and increases maximum tolerated dose >60-fold in preclinical studies
2018 · Leila M. Boustany, Laurie Wong, et al. · Molecular Cancer Therapeutics · 31
Abstract 2975: Development of a probody drug conjugate (PDC) targeting CD71 for the treatment of solid tumors and lymphomas
2016 · Shweta Singh, Amy DuPage, et al. · Cancer Research · 7
Abstract A203: CD3-EGFR bispecific Probody™ therapeutics induced tumor regressions and increased therapeutic window in preclinical studies
2015 · Sherry L. LaPorte, Daniel R. Hostetter, et al. · Molecular Cancer Therapeutics · 4
961 CX-908, a PROBODY ® T cell engager targeting CDH3 and CD3, induces tumor regressions and improves the therapeutic window in preclinical studies
2025 · Erwan Le Scolan, Lauren Kadavy, et al. · Journal for ImmunoTherapy of Cancer · 1
PDF
Data from A Probody T Cell–Engaging Bispecific Antibody Targeting EGFR and CD3 Inhibits Colon Cancer Growth with Limited Toxicity
2023 · Leila M. Boustany, Sherry L. LaPorte, et al.
Data from A Probody T Cell–Engaging Bispecific Antibody Targeting EGFR and CD3 Inhibits Colon Cancer Growth with Limited Toxicity
2023 · Leila M. Boustany, Sherry L. LaPorte, et al.
Supplementary Data from A Probody T Cell–Engaging Bispecific Antibody Targeting EGFR and CD3 Inhibits Colon Cancer Growth with Limited Toxicity
2023 · Leila M. Boustany, Sherry L. LaPorte, et al.
Works count: 8
Citation count: 113
H-index: 4
I10-index: 2
Year
Topic
Type